2020

Results of Annual General Meeting 2020

AGM Investor Presentation 2020

Middle East is next market for PromarkerD immunoassay test

PromarkerD clinical assay performance results published

Change in substantial holding – Lipscombe – PIQ

Change in substantial holding – Dunlop – PIQ

Proteomics receives 1.1 million in R&D tax incentive

Appendix 2A – Completion of Placement

Quarterly Update September 2020 – Appendix 4C

Proposed issue of Securities – PIQ – Ordinary Fully Paid

Proposed issue of Securities – PIQ – Unquoted options

Proteomics International raises $6m in successful Placement

First distribution agreement for PromarkerD immunoassay

PromarkerD international validation study results published

Partnership with QIMR Berghofer targets oesophageal cancer

Change of Director’s Interest Notice

Annual Report to shareholders

Appendix 4E – Preliminary Final Report

Corporate Governance Statement and Appendix 4G

Investor Presentation – August 2020

Proposed issue of Securities – PIQ

Issue of Corporate Advisory Options and Secondary Trading No

Quarterly Update June 2020 – Appendix 4C

PromarkerD Intellectual Property portfolio expands

Updated Trading Policy

Appendix 3Y – Directors on-market purchase of shares

Appendix 2A – Exercise of Employee Options

Big pharma clinical study validates PromarkerD kidney test

PIQ Investor Presentation – 9th June 2020

Proteomics International receives COVID-19 research grants

Appendix 4C – March 2020 Quarterly Update

CE Mark for PromarkerD Immunoassay Kit

Diagnostics R&D expanded: the Promarker™ Pipeline

Proteomics International expands study with US big pharma

Proposed Issue of Securities

Issue of Corporate Advisory Options

Outcome of Extraordinary General Meeting

Proteomics International to patent biomarkers for diagnosis of endometriosis

PIQ Half Year Report Appendix 4D

PromarkerD presented at Australasian Proteomics conference

Appendix 4C – December 2019 Quarterly Update

CE Mark for PromarkerD Hub predictive software for DKD